The weekly term sheet (34)
Biopharma dealmaking slows amid regulatory storm
The week of August 18-23, 2025 marked an unusually subdued period for biopharma transactions,
Company of the week: Palantir
The pharmaceutical industry's adoption of Palantir Technologies reveals a fundamental tension in enterprise software architecture that goes beyond
Fund of the week: ARCH Venture Partners
ARCH Venture Partners has raised over $3 billion for its thirteenth fund, cementing its position as one of biotech'
Collateralized Fund Obligations: The $7 Trillion Question for Biotech Financing
The recent closure of AlpInvest's $1 billion collateralized fund obligation marks a potential inflection point for biotech financing.
The Definitive Guide to Biotech Conference Darwinism: Survival of the Networkiest
Where natural selection meets unnatural hotel ballroom lighting
In the grand ecosystem of biotechnology conferences, where PowerPoint presentations battle for
The silicon valley time machine: why AI's cloud economics are pushing biotech back to the mainframe era
EU AI Act: Pharmaceutical AI Compliance Framework
EU AI Act Classification
High-Risk AI Systems
Pharmaceutical AI Applications
Documentation
Requirements
Risk
Private equity moves deeper into biotech royalties as funding crisis intensifies
Private equity firms deployed $5.42 billion into biotech and pharmaceutical royalty transactions through 2025, marking a 7% increase from
The weekly term sheet (33)
Pharma & biotech deals heat up with $5B+ in transactions
The week of August 11-15, 2025 witnessed a striking bifurcation
Space: the final formulation frontier
These are the voyages of a new class of pharmaceutical pioneers.
Their five-year mission: to explore strange crystallization conditions,
to
Company of the week: Arrakis navigates the undruggable desert
Finding the spice in RNA's vast landscape
Arrakis Therapeutics has positioned itself as a pioneer in RNA-targeted small
